• HOME PAGE
  • ABOUT US
  • OUR TEAM
    • Doctors
    • Nurses
    • Laboratory Technicians
    • Public Relations
    • Support Staff
  • OUR SERVICES
    • Cancer Diagnosis and Treatment
    • Laboratory Services
    • Nursing Services
  • ARTICLES
    • New Developments in Cancer Treatment
    • New Developments in Lung Cancer Treatment
    • New Developments in Early-Stage Breast Cancer Treatment
    • New Developments in the Treatment of Metastatic Breast Cancer
    • New Developments in Colon Cancer Treatment
    • New Developments in Pancreatic Cancer Treatment
    • New Developments in Prostate Cancer Treatment
  • TANSAN IN THE PRESS
  • EVENTS & DEVELOPMENTS
  • VIDEOS
  • CONTACT
+90 212 225 27 56
  • Home
  • New Developments in Colon Cancer Treatment

New Developments in Colon Cancer Treatment

New Developments in Colon Cancer Treatment

Today we have more options in the treatment of colon cancer; however, the important thing is to determine which of these options will benefit which patient. The stage of the disease, the pathology result and the person's general health are evaluated together. The collaborative work of surgical, medical oncology, radiology and pathology specialists determines both the surgical plan and the timing and scope of drug treatment. In some patients with limited spread to the liver or lungs, surgical or regional treatments targeting metastases may also be considered. [1]

One of the important steps in personalized treatment is recognizing the molecular characteristics of the tumor. MMR/MSI analysis provides information about the ability of cancer cells to repair certain errors in DNA. In metastatic disease, the evaluation of targets such as RAS, BRAF and, if necessary, HER2 guides drug selection. These results become meaningful whether the tumor originates from the right or left colon and in conjunction with previous treatments. [1]

One of the significant developments in postoperative treatment in 2026 was the ATOMIC study. In stage III colon cancer with lymph node metastasis and DNA repair defect (dMMR), adding the immunotherapy atezolizumab to standard FOLFOX chemotherapy extended disease-free survival. This approach was approved in the US in 2026. The results are specific to this particular molecular group, not all stage III patients. [2,3]

In inoperable or metastatic disease, the detection of dMMR or high microsatellite instability (MSI-H) can alter the choice of treatment. The combination of pembrolizumab with nivolumab and ipilimumab is among the options that can provide long-term disease control in suitable patients. This dual therapy was approved in the US in 2025. In contrast, immunotherapy is often not a standard option in tumors that do not have these characteristics. [1,4]

Targeted drugs are also expanding their areas of use. In metastatic disease with BRAF V600E mutation, the combination of encorafenib, cetuximab, and fluorouracil-based chemotherapy received full approval in the US in 2026. In patients with KRAS G12C mutation who have previously received the necessary chemotherapy, sotorasib with panitumumab; and in suitable patients who are HER2 positive, do not have RAS mutations, and have progressed after previous treatments, tukatinib with trastuzumab can be options. These drugs are evaluated when the relevant target is identified. [5–7]

The investigation of circulating tumor DNA (ctDNA) in the blood after surgery is also a closely monitored area. This test can provide information about any remaining microscopic disease and the risk of recurrence. However, the DYNAMIC-III results showed that reducing or intensifying chemotherapy based solely on ctDNA results does not always lead to better outcomes in stage III disease. Therefore, the test should not be considered a standalone decision-making tool replacing standard assessments. [8]

New treatments offer hope; however, the benefits they provide to the patient depend on the right choice and regular follow-up. The side effects of the treatment, its impact on bowel function, nutrition, and daily life should be openly discussed. Each option should be evaluated considering the patient's priorities, along with accessibility conditions in Türkiye.

Sources  [1] NCI · Colon cancer  |  [2] ATOMIC · NEJM 2026  |  [3] Atezolizumab · FDA 2026  |  [4] CheckMate-8HW · FDA  |  [5] BRAF · FDA 2026  |  [6] KRAS G12C · FDA  |  [7] HER2 · FDA  |  [8] DYNAMIC-III

Call

Latest News & Announcements

  • Tansan Oncology Celebrates its 30th Anniversary with Pride.

    As Tansan Oncology, we are a passenger in the field of healthcare...
  • Following the Path of Scientific Progress: Participation of Our Clinical Team in the Turkish Medical Oncology Congress 2026

    Closely following the latest developments in the field of oncology...
  • We need to stop fighting death.

    Click to go to the link. He turned his pocket...
  • Müjdat Gezen wrote: Süalp Tansan | Cumhuriyet

    Click here to go to the link. Kandemir (Kond...
  • ‘'Vitamin D plays a vital role in preventing cancer!'’

    Click here to go to the link. Dr. Sualp Tansa...
  • LAW ON THE PROTECTION OF PERSONAL DATA (LPPD) INFORMATION TEXT
  • PERSONAL DATA STORAGE AND DESTRUCTION POLICY
  • POLICY ON THE PROTECTION AND PROCESSING OF SPECIAL CATEGORY PERSONAL DATA
  • DECLARATION OF EXPLICIT CONSENT UNDER THE PERSONAL DATA PROTECTION LAW (KVKK)
  • SATISFACTION SURVEY

Tansan Oncology © 03.07.2026 All rights reserved.
These articles are written for patient information purposes.

TOP
EN
TR
By continuing to use our website, our privacy policy By doing so, you agree to the use of cookies.